However, CD28‐expressing TSH‐CAR‐T cells released higher levels of IL‐2 and IFNr compared to those carrying 4‐1BB, which aligns with existing findings that the CD28 costimulatory molecule induces faster and stronger activation of CAR‐T cells.[45, 46] Importantly, the anti‐tumor activity of TSH‐CAR‐T cells was comparable to that of control CAR‐T cells that target the pan‐tumor antigen B7‐H3. This evidence concerns the gene IFNAR2 and neoplasm.